Literature DB >> 8056688

Structure-activity and structure-side-effect relationships for the quinolone antibacterials.

J M Domagala1.   

Abstract

The fluoroquinolones represent a major class of antibacterials with great therapeutic potential. Over the years, several structure-activity and side-effect relationships have been developed, covering thousands of analogues, in an effort to improve overall antimicrobial efficacy while reducing undesirable side-effects. In this review, the various structural features of the quinolones which govern antibacterial efficacy and influence the side-effect profile are delineated and summarized at the molecular level. Those features which most remarkably enhance antimicrobial effectiveness are: a halogen (F or Cl) at the 8-position which improves oral absorption and activity against anaerobes; an alkylated pyrrolidine or piperazine at C7 which increases serum half-life and potency vs Gram-positive bacteria; and a cyclopropyl group at N1 and an amino substituent at C5, both of which improve overall potency. Some side-effects of the quinolones are class effects, and cannot be modulated by molecular variation. These include gastrointestinal irritation and arthropathy. Several other potential side-effects are directly influenced by structural modification. For example, CNS effects and drug interactions with theophylline and NSAIDs are strongly influenced by the C7 substituent with simple pyrrolidines and piperazines the worst actors. Increasing steric bulk through alkylation ameliorates these effects. Phototoxicity is determined by the nature of the 8-position substituent with halogen causing the greatest photo reaction while hydrogen and methoxy show little light induced toxicity. Genetic toxicity is controlled in additive fashion by the choice of groups at the 1, 7 and 8 positions. From the analysis, those groups which mutually improve efficacy while reducing side-effects are identified. In addition, preclinical models for determining potential side-effects are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056688     DOI: 10.1093/jac/33.4.685

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  107 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Detection and prevention of ocular phototoxicity of ciprofloxacin and other fluoroquinolone antibiotics.

Authors:  Baozhong Zhao; Colin F Chignell; Mustapha Rammal; Frank Smith; Mary G Hamilton; Usha P Andley; Joan E Roberts
Journal:  Photochem Photobiol       Date:  2010-06-01       Impact factor: 3.421

3.  Degradation of ciprofloxacin by cryptomelane-type manganese(III/IV) oxides.

Authors:  Xiao Xiao; Sheng-Peng Sun; Murray B McBride; Ann T Lemley
Journal:  Environ Sci Pollut Res Int       Date:  2012-06-22       Impact factor: 4.223

4.  Mirtazapine therapy for dysgeusia in an elderly patient.

Authors:  Kalpana P Padala; Cheryl K Hinners; Prasad R Padala
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 5.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

6.  Optical control of antibacterial activity.

Authors:  Willem A Velema; Jan Pieter van der Berg; Mickel J Hansen; Wiktor Szymanski; Arnold J M Driessen; Ben L Feringa
Journal:  Nat Chem       Date:  2013-09-15       Impact factor: 24.427

Review 7.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; S Ferrer; E Tudela; M Robert; R Coll; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Bone-targeting of quinolones conjugated with an acidic oligopeptide.

Authors:  Tatsuo Takahashi; Koichi Yokogawa; Naoki Sakura; Masaaki Nomura; Shinjiro Kobayashi; Ken-ichi Miyamoto
Journal:  Pharm Res       Date:  2008-07-29       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.